Bavarian Nordic (OTCMKTS:BVNRY) Share Price Crosses Above Fifty Day Moving Average - What's Next?

Key Points

• Bavarian Nordic stock has surpassed its 50-day moving average of $9.08, reaching a high of $12.50 during trading.
• The company reported a net margin of 21.11% and earnings of $0.13 per share for the last quarter, with an expected EPS of 0.67 for the current fiscal year.
• Bavarian Nordic specializes in developing life-saving vaccines, including those for smallpox, monkeypox, rabies, tick-borne encephalitis, and Ebola.

Shares of Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) passed above its fifty day moving average during trading on Thursday . The stock has a fifty day moving average of $9.08 and traded as high as $12.50. Bavarian Nordic shares last traded at $12.13, with a volume of 110,832 shares changing hands.

Bavarian Nordic Stock Performance

The company has a market cap of $2.88 billion, a price-to-earnings ratio of 15.23 and a beta of 1.36. The business's 50 day moving average price is $9.24 and its 200-day moving average price is $8.43.

Bavarian Nordic (OTCMKTS:BVNRY - Get Free Report) last announced its quarterly earnings data on Friday, May 9th. The company reported $0.13 earnings per share (EPS) for the quarter. Bavarian Nordic had a net margin of 21.11% and a return on equity of 11.89%. The company had revenue of $189.89 million during the quarter. On average, equities research analysts expect that Bavarian Nordic will post 0.67 earnings per share for the current fiscal year.

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name.